In short
Tirofiban Hydrochloride Monohydrate, a medication used in certain heart conditions, is currently being studied in clinical trials for its potential benefits in treating acute ischemic stroke. This article explores the ATILA project, a clinical trial investigating the use of Tirofiban compared to aspirin in patients with acute ischemic stroke caused by tandem lesions. We'll discuss the trial's objectives, eligibility criteria, and potential outcomes, providing valuable insights into this promising area of stroke treatment research.
At a glance
- Trial Name
- ATILA Project (Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion)
- Main Objective
- Assess efficacy and safety of tirofiban vs. aspirin in acute ischemic stroke patients with tandem lesions
- Primary Outcomes
- Carotid reocclusion, platelet aggregation, symptomatic intracranial hemorrhage
- Secondary Outcomes
- Functional prognosis at 90 days, rescue therapy rate, biomarker identification
- Key Inclusion Criteria
- Adults with acute ischemic stroke due to tandem lesion, ASPECTS ≥6, need for thrombectomy and cervical stent
- Key Exclusion Criteria
- Age <18, allergies to study drugs, high bleeding risk, severe comorbidities
- Drug Information
- Tirofiban (AGRASTAT), 50 micrograms/ml solution for infusion, max daily dose 500 micrograms
What is Tirofiban Hydrochloride Monohydrate?
Tirofiban Hydrochloride Monohydrate is an active substance used in a medication called Agrastat. It belongs to a class of drugs known as platelet aggregation inhibitors, which help prevent blood clots from forming. Tirofiban is primarily used in the treatment of certain cardiovascular conditions, particularly those involving blood vessel blockages.
Medical Conditions Treated
Tirofiban is primarily used to treat acute ischemic stroke, a condition where blood flow to the brain is blocked, potentially causing damage to brain tissue. Specifically, it's being studied for use in patients with acute ischemic stroke due to a tandem lesion. A tandem lesion refers to a situation where there are two blockages: one in the neck (carotid) artery and another in a brain artery.
How Tirofiban Works
Tirofiban works by preventing platelets (small blood cells involved in clotting) from sticking together. This action helps to prevent the formation of blood clots or break down existing clots, which can improve blood flow to the brain in cases of ischemic stroke.
How Tirofiban is Administered
Tirofiban is given as a solution for intravenous infusion. This means it's delivered directly into the bloodstream through a vein, usually in a hospital setting. The typical concentration is 50 micrograms per milliliter.
Current Clinical Trial: The ATILA Project
A clinical trial called the ATILA Project (Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion) is currently underway to study the effectiveness of Tirofiban compared to aspirin in treating acute ischemic stroke caused by tandem lesions.
Main Objectives of the Trial:
- To assess the efficacy and safety of Tirofiban versus aspirin in patients with ischemic stroke due to tandem injury.
- To determine the rate of reocclusion (re-blockage of blood vessels).
- To evaluate the rate of symptomatic bleeding, defined as any hemorrhagic transformation associated with a worsening of 4 or more points on the National Institutes of Health Stroke Scale.
Eligibility for the ATILA Trial
To participate in the ATILA trial, patients must meet certain criteria:
- Have acute ischemic stroke of the anterior territory secondary to a tandem lesion
- Be indicated for thrombectomy treatment (a procedure to remove blood clots)
- Need cervical stent placement
- Be 18 years or older
- Have an ASPECTS score (a measure of stroke severity) of 6 or higher
Potential Benefits of Tirofiban
The ATILA trial aims to determine if Tirofiban offers advantages over aspirin in treating acute ischemic stroke due to tandem lesions. Potential benefits being studied include:
- Reduced rate of reocclusion (re-blockage of blood vessels)
- Improved functional outcomes at 90 days after treatment
- Reduced need for rescue therapy during the procedure
Precautions and Exclusion Criteria
Certain conditions may prevent a patient from using Tirofiban or participating in the ATILA trial. These include:
- Documented allergy to Tirofiban or aspirin
- History of low platelet count (platelets <100,000)
- Current anticoagulant treatment
- High risk of bleeding
- Active peptic ulcer in the last 3 months
- Severe allergy to contrast medium
It's important to discuss your full medical history with your healthcare provider to determine if Tirofiban is appropriate for you.